(SIX: SFZN) At the 2016 Annual Meeting, the Board of Directors of Siegfried Holding AG will recommend the nomination to the Board of Ulla Schmidt, Vice President of the German Bundestag, and Martin Schmid, Member of Switzerland’s Council of State.
Ulla Schmidt was elected to the German Bundestag in 1990 and named its Vice-President in 2013. She served as Minister of Health on the Cabinet of the Federal Republic of Germany from 2001 to 2009. She was an undergraduate psychology student at the University of Aachen and graduated with a teaching diploma from that university. Prior to her election to the Bundestag she served in public office in Aachen, including the city council.
Martin Schmid was elected Councilor of State for Canton Grisons in 2011. Prior, from 2003 to 2011, he served as member of the Canton Grisons government, where he directed the Department of Justice, Security and Health and subsequently the Department of Finance. Martin Schmid is an attorney at law and serves on several corporate boards in the fields of energy and construction. He graduated from the University of St. Gallen where he was awarded a Ph.D. in 2005.
Andreas Casutt, Chairman, Colin Bond, Wolfram Carius, Reto Garzetti und Thomas Villiger will stand for re-election.
Chairman Andreas Casutt: “On behalf of the Board I am very pleased that we are able to recommend Ulla Schmidt and Martin Schmid for nomination to the Board. Both are experienced professionals with many years of service on political and professional bodies with a strong influence on the pharmaceutical market. They will be able to provide support to Siegfried in those countries, especially, in which our most important sites are located and where we employ the highest number of employees.”
For further information:
Peter Gehler, Chief Communications Officer
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16
Siegfried Holding AG
Untere Bruehlstrasse 4
Tel. +41 62 746 11 11
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta, France and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 2400 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.